Topic summary

Second pass at: Historical amylin analogues and what happened to them

Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrilintide cagrisema randomised trial Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 20, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

BirkelandTL3Regular5 Jan 2025#4

citation_index, post #2: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

post #2 answers the question as asked. The question underneath it is different.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

19 likes in reply to #2 19mo

ar.kravchenkoTL2 Moderator9 Jan 2025#7

Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.

27 likes 19mo

r.vukovicTL2 Moderator16 Jan 2025#13

ar.kravchenko, post #7: Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years. Go to post

What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.

17 likes in reply to #7 18mo

r.mcalisterTL3Regular17 Jan 2025#14

r.nakamura, post #11: I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient. Go to post

On post #10 — agreed on the reasoning, with one qualification.

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

32 likes in reply to #11 18mo

k.otieno_statsTL3Statistician21 Jan 2025#18

tracked_parcel, post #16: Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

Worth separating two things that post #14 runs together.

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

24 likes in reply to #16 18mo

Read the full topic (20 posts)

This topic was referenced in

The CagriSema phase 2 paper and what a fixed combination buys — the long versionCompounds › Cagrilintide & amylin analogues · 158 replies

This topic was closed 180 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support…		2	25k	11mo
Second pass at: Cagrilintide molecular characteristics and analytical considerations Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrisema On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019).…		4	5k	21d
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial cagrilintide On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+27	31	671	12mo
Why cagrilintide alone is discussed so much less than in combination — does this still hold? Compounds › Cagrilintide & amylin analogues cagrisema randomised trial cagrilintide effect size Solved Under review Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…	+27	31	1.2k	22h
Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues effect size randomised trial cagrilintide cagrisema Solved Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SCALE ( N Engl J Med , 2015) and…	+128	142	38k	13mo

Related topics — sharing the tags amylin analogues, effect size, cagrilintide

Topic	Participants	Replies	Views	Activity
Criticising the method without criticising the authors Evidence › Study critique disputed observational data confounding effect size Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim…	+55	61	60k	15mo
Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide retatrutide effect size preprint Solved The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…	+71	80	38k	11mo
[2026 update] Journal club: is percentage weight change the right endpoint? Evidence › Journal club effect size risk of bias randomised trial Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with…	+105	118	18k	11mo
The C-cell question: rodent findings and their human context Compounds › Semaglutide STEP programme type 2 diabetes effect size Closed Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a…	+41	45	24k	12mo
Adjudicated events and why the definition matters — the long version Evidence › Trials intention to treat estimand randomised trial discontinuation & dropout Adjudicated events and why the definition matters — the long version Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021) with STEP 4 ( JAMA…	+125	146	13k	15mo